Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to 504.58%.

  • Bicycle Therapeutics' EBITDA Margin rose 14720600.0% to 504.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 4374.93%, marking a year-over-year increase of 72039800.0%. This contributed to the annual value of 13967.33% for FY2024, which is 105266700.0% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported EBITDA Margin of 504.58% as of Q3 2025, which was up 14720600.0% from 2768.97% recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' EBITDA Margin ranged from a high of 326.02% in Q4 2023 and a low of 2768.97% during Q2 2025
  • Its 5-year average for EBITDA Margin is 783.67%, with a median of 624.78% in 2025.
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 19204400bps in 2022, then tumbled by -23403200bps in 2025.
  • Over the past 5 years, Bicycle Therapeutics' EBITDA Margin (Quarter) stood at 2279.0% in 2021, then surged by 84bps to 358.56% in 2022, then surged by 191bps to 326.02% in 2023, then crashed by -51bps to 159.88% in 2024, then plummeted by -416bps to 504.58% in 2025.
  • Its last three reported values are 504.58% in Q3 2025, 2768.97% for Q2 2025, and 624.78% during Q1 2025.